PT614355E - Vacinas antitumorais - Google Patents

Vacinas antitumorais

Info

Publication number
PT614355E
PT614355E PT93900706T PT93900706T PT614355E PT 614355 E PT614355 E PT 614355E PT 93900706 T PT93900706 T PT 93900706T PT 93900706 T PT93900706 T PT 93900706T PT 614355 E PT614355 E PT 614355E
Authority
PT
Portugal
Prior art keywords
antitumor vaccines
antigen
antitumor
vaccines
express
Prior art date
Application number
PT93900706T
Other languages
English (en)
Inventor
Lynn E Spitler
Original Assignee
Jenner Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenner Technologies filed Critical Jenner Technologies
Publication of PT614355E publication Critical patent/PT614355E/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT93900706T 1991-11-26 1992-11-25 Vacinas antitumorais PT614355E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80047491A 1991-11-26 1991-11-26

Publications (1)

Publication Number Publication Date
PT614355E true PT614355E (pt) 2002-07-31

Family

ID=25178488

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93900706T PT614355E (pt) 1991-11-26 1992-11-25 Vacinas antitumorais

Country Status (11)

Country Link
US (1) US5738867A (pt)
EP (1) EP0614355B1 (pt)
JP (2) JPH07501548A (pt)
AT (1) ATE212540T1 (pt)
AU (1) AU675215B2 (pt)
CA (1) CA2123696C (pt)
DE (1) DE69232395T2 (pt)
DK (1) DK0614355T3 (pt)
ES (1) ES2171410T3 (pt)
PT (1) PT614355E (pt)
WO (1) WO1993010763A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana Farber Cancer Inst Inc Induktion der antworten zytotoxischer t-lymphozyten
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995003035A1 (en) * 1993-07-23 1995-02-02 Massachusetts Institute Of Technology Polymerized liposomes with enhanced stability for oral delivery
JPH09504000A (ja) * 1993-08-11 1997-04-22 ジェナー テクノロジーズ 前立腺癌ワクチン
FR2716373B1 (fr) * 1994-02-23 1996-05-03 Pasteur Institut Liposomes, et leur utilisation pour l'obtention de vaccins.
US6942862B2 (en) 1996-04-01 2005-09-13 University Of Washington Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins
US6541212B2 (en) * 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
WO1998053799A2 (en) * 1997-05-28 1998-12-03 Jenner Biotherapies, Inc. Immunogenic compositions
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
WO2004015098A2 (en) * 2002-08-07 2004-02-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Rhesus epithelial cell adhesion molecule, nucleic acid encoding the same, and uses thereof
AT500648B1 (de) * 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
WO2004093808A2 (en) * 2003-04-22 2004-11-04 Maxygen, Inc. Novel tumor-associated antigens
EP1812052A1 (en) * 2004-11-02 2007-08-01 Biomedical Research Models, Inc. Methods of cancer treatment/prevention using cancer cell-specific surface antigens
WO2023122075A1 (en) * 2021-12-20 2023-06-29 Ohio State Innovation Foundation Compositions comprising sterol-amino-phosphate compounds and methods of making and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1165238A (en) * 1980-03-12 1984-04-10 Demetrios P. Papahadjopoulos Activated liposomes and method
US4343895A (en) * 1980-05-23 1982-08-10 Stephen Sugaar Encapsulated antigenic tumor specific substances and methods for detecting cancer using said substances
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US5141742A (en) * 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
JPH02188532A (ja) * 1989-01-17 1990-07-24 Otsuka Pharmaceut Co Ltd リポソームワクチン

Also Published As

Publication number Publication date
DE69232395D1 (de) 2002-03-14
EP0614355A4 (en) 1997-10-01
EP0614355A1 (en) 1994-09-14
AU675215B2 (en) 1997-01-30
DK0614355T3 (da) 2002-03-11
WO1993010763A1 (en) 1993-06-10
CA2123696A1 (en) 1993-06-10
CA2123696C (en) 2002-07-02
JPH07501548A (ja) 1995-02-16
ES2171410T3 (es) 2002-09-16
JP2002104993A (ja) 2002-04-10
ATE212540T1 (de) 2002-02-15
AU3228393A (en) 1993-06-28
EP0614355B1 (en) 2002-01-30
US5738867A (en) 1998-04-14
DE69232395T2 (de) 2002-11-14

Similar Documents

Publication Publication Date Title
ATE212540T1 (de) Antitumorvakzine
FI924069A0 (fi) Terapeutiskt anvaendbara peptider och peptidfragment.
DK0511917T3 (da) Glycosylerede prodrugs, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK0642355T3 (da) Kombinerede vacciner, der omfatter hepatitis B-overfladeantigen og andre antigener
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
MY113428A (en) Hepatitis b vaccine
KR960701211A (ko) 암 백신을 제조하는 방법(process for preparing cancer vaccines)
CA2185470A1 (en) Compositions and methods for vaccines comprising .alpha.-galactosyl epitopes
MY100952A (en) Immune response to tumours and viruses induced by anti- idiotype antibodies
EP0661061A3 (en) Vaccine suitable to elicit an immune response against N-Glycolized gangliosides and their use in anti-cancer drugs.
DK169987D0 (da) Human tumor-associated antigen, ca-ou1
EP0951475A4 (en) Vaccine against metastatic colorectal cancer.
IL71953A (en) Malaria associated antigen,process for preparation thereof and vaccine comprising it
AU6435596A (en) Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
GB9018061D0 (en) Compositions for vaccines
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
EP0344211A4 (en) MONOCLONAL ANTIBODIES IN VACCINE COMPOSITIONS.
DK175091D0 (da) Human tumor associated antigens, ca-ou2 and ca-ou3
IT217731Z2 (it) Dispositivo autoirrorante per colture da vaso o simili.
ZA923759B (en) Tumor rejection antigen precursors,tumor rejection antigens and uses thereof
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.
DK182188D0 (da) Humant tumorassocieret antigen